基于SCOT和QUASAR 2试验的II-III期结直肠癌瘤内免疫浸润多重分析与预后:一项回顾性分析
该回顾性分析利用多重免疫荧光染色评估SCOT和QUASAR 2试验中II-III期结直肠癌患者肿瘤组织内CD8+、CD20+、FoxP3+、CD68+细胞密度,发现上皮内CD8与间质FoxP3联合指标(CD8IE-FoxP3IS)具有独立预后价值,其性能与Immunoscore相似,并在QUASAR 2队列中验证。
要点
- 上皮内CD8和间质FoxP3密度与无复发生存期独立相关
- CD8IE-FoxP3IS联合指标预后价值优于单一标志物,性能类似Immunoscore
- CD8IE-FoxP3IS在QUASAR 2队列中验证了连续变量和低vs高密度分组的预后价值
核心结论
- 联合评估CD8IE和FoxP3IS可能有助于优化结直肠癌风险分层。
- 研究FoxP3IS细胞作为结直肠癌免疫治疗靶点可能值得开展。
研究设计与样本
- 回顾性分析SCOT试验(ISRCTN59757862)和QUASAR 2试验(ISRCTN45133151)中II-III期结直肠癌患者的肿瘤样本。
- 采用组织芯片多重免疫荧光染色评估上皮内和间质CD8+、CD20+、FoxP3+、CD68+细胞密度。
- SCOT队列用于发现,QUASAR 2队列用于验证,采用Cox回归评估无复发生存期预后价值。
- 最终纳入SCOT试验2340例和QUASAR 2试验1069例进行分析。
主要发现
- SCOT队列单变量分析显示上皮内CD8(CD8IE)连续变量与无复发生存期强相关(第75 vs 第25百分位HR 0.73,95%CI 0.68-0.79,p=2.5×10-16)。
- 间质FoxP3(FoxP3IS)亦强相关(HR 0.71,95%CI 0.64-0.78,p=1.5×10-13),上皮内FoxP3(FoxP3IE)关联较弱(HR 0.89,95%CI 0.84-0.96,p=1.5×10-4)。
- CD8IE-FoxP3IS联合指标连续变量校正HR(第75 vs 第25百分位)为0.70(95%CI 0.63-0.78,p=5.1×10-11),性能与Immunoscore相似。
- CD8IE-FoxP3IS分类变量:中vs高密度校正HR 1.68(95%CI 1.29-2.20,p=1.3×10-4),低vs高密度校正HR 2.58(95%CI 1.91-3.49,p=7.9×10-10)。
- QUASAR 2验证:连续变量校正HR 0.84(95%CI 0.73-0.96,p=0.012),低vs高密度校正HR 1.80(95%CI 1.17-2.75,p=0.0071),中vs高密度校正HR 1.30(95%CI 0.89-1.88,p=0.17,未达统计学显著)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour-infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer. The added prognostic value of other infiltrating immune cells is unclear and so we sought to investigate their prognostic value in two large clinical trial cohorts. METHODS: We used multiplex immunofluorescent staining of tissue microarrays to assess the densities of CD8+, CD20+, FoxP3+, and CD68+ cells in the intraepithelial and intrastromal compartments from tumour samples of patients with stage II-III colorectal cancer from the SCOT trial (ISRCTN59757862), which examined 3 months versus 6 months of adjuvant oxaliplatin-based chemotherapy, and from the QUASAR 2 trial (ISRCTN45133151), which compared adjuvant capecitabine with or without bevacizumab. Both trials included patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1. Immune marker predictors were analysed by multiple regression, and the prognostic and predictive values of markers for colorectal cancer recurrence-free interval by Cox regression were assessed using the SCOT cohort for discovery and QUASAR 2 cohort for validation. FINDINGS: After exclusion of cases without tissue microarrays and with technical failures, and following quality control, we included 2340 cases from the SCOT trial and 1069 from the QUASAR 2 trial in our analysis. Univariable analysis of associations with recurrence-free interval in cases from the SCOT trial showed a strong prognostic value of intraepithelial CD8 (CD8IE) as a continuous variable (hazard ratio [HR] for 75th vs 25th percentile [75vs25] 0·73 [95% CI 0·68-0·79], p=2·5 × 10-16), and of intrastromal FoxP3 (FoxP3IS; 0·71 [0·64-0·78], p=1·5 × 10-13) but not as strongly in the epithelium (FoxP3IE; 0·89 [0·84-0·96], p=1·5 × 10-4). Associations of other markers with recurrence-free interval were moderate. CD8IE and FoxP3IS retained independent prognostic value in bivariable and multivariable analysis, and, compared with either marker alone, a composite marker including both markers (CD8IE-FoxP3IS) was superior when assessed as a continuous variable (adjusted [a]HR75 vs 25 0·70 [95% CI 0·63-0·78], p=5·1 × 10-11) and when categorised into low, intermediate, and high density groups using previously published cutpoints (aHR for intermediate vs high 1·68 [95% CI 1·29-2·20], p=1·3 × 10-4; low vs high 2·58 [1·91-3·49], p=7·9 × 10-10), with performance similar to the gold-standard Immunoscore. The prognostic value of CD8IE-FoxP3IS was confirmed in cases from the QUASAR 2 trial, both as a continuous variable (aHR75 vs 25 0·84 [95% CI 0·73-0·96], p=0·012) and as a categorical variable for low versus high density (aHR 1·80 [95% CI 1·17-2·75], p=0·0071) but not for intermediate versus high (1·30 [0·89-1·88], p=0·17). INTERPRETATION: Combined evaluation of CD8IE and FoxP3IS could help to refine risk stratification in colorectal cancer. Investigation of FoxP3IS cells as an immunotherapy target in colorectal cancer might be merited. FUNDING: Medical Research Council, National Institute for Health Research, Cancer Research UK, Swedish Cancer Society, Roche, and Promedica Foundation.
引用
- Frei AL, McGuigan A, Sinha RRAK, et al. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis. Lancet Oncol. 2024. PMID: 38301689. doi:10.1016/S1470-2045(23)00560-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。